Form 8-K - Current report:
SEC Accession No. 0001641172-25-007852
Filing Date
2025-04-30
Accepted
2025-04-30 16:57:42
Documents
15
Period of Report
2025-04-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 38059
2 EX-10.1 ex10-1.htm EX-10.1 48901
  Complete submission text file 0001641172-25-007852.txt   335212

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE asbpw-20250424.xsd EX-101.SCH 3845
4 XBRL DEFINITION FILE asbpw-20250424_def.xml EX-101.DEF 28321
5 XBRL LABEL FILE asbpw-20250424_lab.xml EX-101.LAB 37875
6 XBRL PRESENTATION FILE asbpw-20250424_pre.xml EX-101.PRE 26533
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 7383
Mailing Address 194 CANDELARO DRIVE, #233 HUMACAO PR 00791
Business Address 194 CANDELARO DRIVE, #233 HUMACAO PR 00791 561-704-8527
Aspire Biopharma Holdings, Inc. (Filer) CIK: 0001847345 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41293 | Film No.: 25896468
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)